+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treosulfan as an alternative conditioning agent in bone marrow transplantation

Treosulfan as an alternative conditioning agent in bone marrow transplantation

Blood 94(10 SUPPL 1 PART 2): 324b, Nov 15

(PDF emailed within 1 workday: $29.90)

Accession: 035985734

Download citation: RISBibTeXText

Related references

Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning. Pediatric Blood & Cancer 62(2): 299-304, 2014

Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. Immunopharmacology and Immunotoxicology 31(4): 595-600, 2010

Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution. Immunopharmacology and Immunotoxicology 36(2): 158-164, 2014

European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. Pediatric Blood & Cancer 63(1): 139-148, 2016

Allogeneic hematopoietic stem cell transplantation after treosulfan/fludarabine conditioning in high-risk patients with hematologic malignancies Dose escalation of treosulfan. Blood 102(11): 467a, November 16, 2003

The use of a reduced BU/CY II conditioning regimen for allogeneic bone marrow transplantation results in decreased regimen-related toxicity and graft-versus-host disease An alternative to conventional and non-myeloablative conditioning regimens. Blood 98(11 Part 2): 348b, November 16, 2001

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. Journal of Clinical Oncology 32(31): 3497-3505, 2014

Bone marrow transplantation for multiple myeloma with busulfan and cyclophosphamide conditioning regimen slow disappearance of plasma cells from bone marrow following transplantation. Experimental Hematology (Charlottesville) 19(6): 574, 1991

Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation. Plos One 9(9): E107155-E107155, 2015

High dose rate total body irradiation and cyclophosphamide as conditioning regimen for bone marrow transplantation in children experience of padua italy bone marrow transplantation group. Journal of Cellular Biochemistry Supplement (10 PART D): 239, 1986

Prenatal tolerance induction facilitates post-natal bone marrow transplantation using Busulfan as a single conditioning agent. Blood 102(11): 457a, November 16, 2003

Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biology of Blood and Marrow Transplantation 10(4): 236-245, 2004

Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation?. Leukemia & Lymphoma 25(3-4): 217-224, 1997

Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 77(7): 1593-1598, 1991

Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group. Journal of Clinical Oncology 17(12): 3729-3735, 1999